Saturday, November 19, 2022
Workshop Summary
The Wharton Club of Hong Kong along with Insead Alumni Association of Hong Kong, is delighted to launch our next Workshop series on Investing in Healthcare Biotech, on Saturday 19th November 2022 (Full Day from 9:15 AM to 5:00 PM including lunch) by fellow Wharton alumni Bosun Hau WG'09, Managing Director, Tybourne Capital, and Thian Chew G'03 WG'03, Chairman & CEO, Invion, a life sciences company developing a novel next generation Photodynamic Therapy (PDT) for the treatment of cancers and other diseases. Thian is also Adjunct Professor teaching at HKUST in the Life Sciences and Business School.
The Wharton Workshop series aims at providing deep subject matter expertise to Alumni and is focused towards serious learning, targeting a standard comparable to what one would expect at a Wharton class in Philadelphia.
Content Summary: Healthcare biotech is a specialized sector but with the global impact from the COVID-19 pandemic and greater attention on broader healthcare priorities, it has emerged as an area that has gained significant attention from investors and the general public.
In this workshop, we will introduce the biotechnology industry with a particular focus on the healthcare and biomedical sector. We will examine the sector both from an operator as well as an investor perspective with a view to providing participants with practical insights and takeaways.
This workshop is specifically geared to those who are new to healthcare biotech investing. No prior biotech or investment knowledge is required although some background in either will be helpful.
Venue:Centricity , Chater House https://www.centricity.com.hk/
Price: HKD 1,500 per head (Non-Refundable), including a Yumcha Lunch at Centricity
Guests: Guests of Wharton and Insead Alumni are welcome, but preference will be given to Alumni
Dress Code: Business Casual/Informal
VERY IMPORTANT Covid Protocols: All participants need to follow all applicable social distancing norms that the venue would impose as per the prevailing Social Distancing norms of the Govt of HK-SAR on the day of the event, including but not limited to: being fully vaccinated for Covid-19, prior to the date of the event, using the Leave Home Safe App / QR code for proof of vaccination and having a RAT Test photo taken less than 24 hours before the event.
Agenda (Full Day 9:15 AM - 5:00 PM)
Registration & Housekeeping
9:15 AM - 9:30 AM
Session 1: Foundations – Overview of Biotechnology Across Industry and Within Healthcare
9:30 AM - 11:00 AM
- Overview of the biotechnology industry – eg, agriculture, industrial, marine, environmental, food, bioinformatics
- Biotechnology in Healthcare: Unmet medical needs and healthcare priorities
- Diseases in context, where is R&D spend
- Healthcare ecosystem stakeholders – eg, biotech, big pharma, clinicians, patients, insurers, regulators
- Regulatory and commercialisation pathways: eg, therapeutics, diagnostics, devices, nutraceuticals, cosmeceuticals
- Emergence of China in medical innovation
Break
11:00 AM - 11:15 AM
Session 2: Biomedical Industry: A Deeper Dive
11:15 AM - 12:30 AM
- Drug development process and the valley of death
- Balancing unmet medical needs with economics: Anti-microbial resistance vs cancer
- Creating impact across the broader healthcare ecosystem: The COVID19 experience
Lunch
12:30 PM - 1:45 PM: Yumcha Lunch at Centricity, Chater House
Session 3: Investing in Biotech
1:45 PM - 3:15 PM
- Biotech sector market trends
- Public vs. Private
- US vs. Asia
- How is investing in biotech different?
- De-risking is value creation
- Investment framework
- Types of risk:
- Technical
- Clinical
- Regulatory
- Commercial
- Competition
- Financing
- Valuation Methodologies
- Exit Pathways
- Types of risk:
- Case study
Break
3:15 PM - 3:30 PM
Session 4: Investment Case Study: Invion (ASX: IVX)
3:30 PM - 5:00 PM
- Presentation of biotech company, Invion Limited by CEO (Thian Chew)
- Investor analysis of company (Bosun Hau)
- Lessons learned and takeaways
Faculty Bio
THIAN CHEW G'03 WG'03
Mr. Thian Chew is Chairman & CEO of Invion Limited (ASX:IVX), a life-sciences company leading the global research and development of PhotosoftTM technology, a next generation photodynamic therapy (PDT), for the treatment of a range of cancers, as well as atherosclerosis and infectious diseases. He is also Executive Chairman of Chronic Airway Therapeutics, a clinical stage company focused on developing novel therapies for chronic airway diseases, as well as Co-Founder of Starlight Dermal, a startup that uses proprietary biotech ingredients in skincare.
Mr. Chew is Managing Partner at Polar Ventures, and was an Executive Director at Goldman Sachs (New York, Hong Kong) responsible for the firm’s proprietary investments. He also spent a decade at KPMG Consulting taking a number of roles across Asia Pacific including leading several operational restructuring and business performance improvement programs.
He holds an MBA, Wharton School (Palmer Scholar), MA, Lauder Institute, Uni. Pennsylvania, and B. Information Systems, Monash University. Mr. Chew is also an Adjunct Professor at the Hong Kong University of Science & Technology’s Schools of Business as well as Life Sciences.
BOSUN HAU WG'09
Mr. Bosun Hau is a Managing Director, Partner and Head of Private Investments at Tybourne Capital Management, a Hong Kong based global public and private equity investment management firm. Previously, Mr. Hau served as a Managing Director and Partner at Sailing Capital, a Hong Kong and Shanghai based global private equity firm. Mr. Hau also has served as a Partner of MVM Partners LLP, a Boston and London based healthcare investment firm, as a Management Consultant with McKinsey & Company in Southeast Asia, and as an early stage biotechnology investor with S.R. One Ltd, GlaxoSmithKline’s corporate venture group. Earlier in his career, Mr. Hau served as an equity research analyst covering the medical device and pharmaceutical sectors for Prudential Securities, Inc. and JP Morgan Securities, Inc. Mr. Hau started his career in the commercial organization at Eli Lilly & Company.
Mr. Hau currently is a member of the boards of directors several private life sciences, fintech, consumer, and TMT companies in the US, EU and Asia. Mr. Hau has served as a director or observer to more than 20 publicly listed and private companies. Mr. Hau also is a Board Overseer of Beth Israel Deaconess Medical Center in Boston, a major teaching hospital of Harvard Medical School, and a Leadership Fellow of The Johns Hopkins University.
Mr. Hau received a B.S. in Molecular and Cellular Biology, a B.S.H.S. in Physiological Sciences and a B.A. in Psychology from the University of Arizona, an M.Sc. in Biotechnology from Johns Hopkins University and an M.B.A in Finance and Health Management from the Wharton School at the University of Pennsylvania.
